Enzalutamide shows positive outcome in TERRAIN trial

A media release issued today by Medivation and Astellas Pharma, based on data presented at the European Association of Urology meeting in Madrid, Spain, states that enzalutamide appears to extend progression-free survival (PFS) better than bicalutamide in the randomized, Phase II TERRAIN trial. … READ MORE …

How much time is there to make decisions about treatment for low-risk patients?

In recent years there has been a widely acknowledged, if unconfirmed, assumption that men initially diagnosed with low-risk prostate cancer (clinical stage T1-2a, PSA < 10 ng/ml; and Gleason 3 + 3 = 6 or lower) had plenty of time to come to a good decision about their management options, and did not need to rush such decisions. … READ MORE …

Published data on Klotz’s active surveillance series at c. 20 years

In a report published on line on Monday, in the Journal of Clinical Oncology, Klotz et al. have now provided peer-reviewed data from their nearly 20-year-long series of patients managed on active surveillance. … READ MORE …

Short-term outcomes after radical prostatectomy and surgeon training/practice site

Now here’s some data that may cause a bit of a furore … so before the US-based urologists get upset, we’d like to point out that this is a Canadian study based on data from members of the Canadian urology community in a single, unidentified Canadian province! … READ MORE …

PSA doubling time, seminal vesicle invasion, and efficacy of salvage radiation therapy

A small study from one hospital in Norway has suggested that PSA doubling times after surgery may predict the value of salvage radiation therapy alone as a second line form of therapy. … READ MORE …

Prostate cancer risk, outcomes, and quality of life; exercise affects all of these

The November issue of the AUA News carries a clear and succinct article directed to urologists about the value of exercise in the prevention and management of prostate cancer. Alas, the full text of this article is only available to members of the American Urological Association (AUA). … READ MORE …

Is treatment with degarelix really “better” than treatment with an LHRH agonist? Part II

Yesterday we commented (by request) on a paper by Klotz et al. suggesting that initial treatment with the LHRH antagonist degarelix might have benefits compared to initial treatment with an LHRH agonist such as leuprolide or goserelin acetate. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,254 other followers